Review Papers Claim by Claim

Key method highlights (paper, directly extracted)

• Semi-automated 96‑well positive-pressure IP (Tecan Resolvex A200) with W6/32 (pan‑MHC‑I) and PdV5.2 (pan‑MHC‑II) antibodies Gul et al., methods and data
• MS analysis on timsTOF SCP (DDA‑PASEF) with IM polygons adapted to immunopeptidomics; multi-engine search (MSFragger, Comet, Sage, PEAKS) and TIMS‑2 rescoring for identification stringency Gul et al., acquisition and search pipeline

Critical appraisal (evidence-based)

• Strengths: Carefully optimized low‑volume lysis (100 µL) and positive‑pressure 96‑well IP reduce transfers and sample loss, enabling thousands of peptide IDs at low input; raw data are available for reanalysis (PRIDE PXD062352) which supports reproducibility Gul et al., strengths & data
• Limitations / blindspots: Results are cell‑line and allele dependent (JY, HeLa, U937) so generalization to diverse primary tissues and rarer HLA haplotypes requires demonstration; proportion of predicted non‑binders increases at very low inputs (possible contaminants or false positives) and keratin/contaminant fraction was noted by authors Gul et al., limitations noted
• Quantitative claims are supported by FragPipe/IonQuant + limma statistics; the authors correctly acknowledge the limitation that the differential test does not impute missing values and so will miss peptides exclusive to one condition unless alternative detection metrics are used (which they also applied) Gul et al., quantification approach
• Comparison to prior art: Builds on and combines ideas from high‑throughput 96‑well IP (Chong et al., 2018) and recent TIMS/PASEF advances; Gul et al. reduce input volumes and demonstrate comparable bacterial antigen discovery with ~30× lower input than earlier work (their own prior Listeria studies) Chong et al., 96-well immunopeptidomics (2018)

Practical notes for adopters

1. Re-run identification pipeline (MSFragger/Comet/Sage/PEAKS + TIMS‑2 Rescore) on PXD062352 to verify peptide lists and bacterial hits; raw files available in PRIDE (PXD062352) per authors Gul et al., PRIDE deposition PXD062352
2. Include blank / process controls and keratin depletion steps when working at ultra-low inputs to reduce contaminants that can dominate spectra at low peptide mass.
3. Validate bacterial immunopeptides by orthogonal targeted MS (PRM/SRM) or synthetic-peptide spectral matching, especially for vaccine-candidate selection.

Author review links

Primary citation (paper under review):

Gul et al., report the full workflow, numerical outputs, method details and PRIDE deposition required for reproducible adoption and reanalysis Gul et al., platform paper

Contextual reference (96‑well precedent): The 96‑well positive‑pressure approach was introduced and validated previously, which Gul et al. extend and miniaturize by reducing lysis volume and tuning flow/plates for positive‑pressure automation Chong et al., 96-well immunopeptidomics